Director at Mainz Biomed (MYNZ) buys 685,000 common shares

Rhea-AI Filing Summary

Mainz Biomed N.V. director Kevin Donahue reported buying common stock in the company. On October 17, 2025, he purchased 685,000 shares at a price of $1.51 per share, leaving him with a total of 685,000 shares beneficially owned in a direct account after the transaction. This Form 4/A is an amendment correcting a prior insider transaction report that was originally filed on 01/16/2026.

Insights

Equity markets and governance analyst

Director Kevin Donahue reports buying 685,000 Mainz Biomed shares at $1.51 in an amended Form 4.

The filing shows Kevin Donahue, a director of Mainz Biomed N.V., executed an open-market or similar purchase transaction coded "P" on 10/17/2025. He acquired 685,000 shares of common stock at a price of $1.51 per share, and his directly held beneficial ownership after the transaction is reported as 685,000 shares.

This document is marked as a Form 4/A amendment, referencing an original report filed on 01/16/2026, indicating a correction to previously reported details rather than a new transaction on the amendment date. The filing does not provide additional context such as total shares outstanding, so the broader ownership impact relative to the company’s equity base cannot be assessed from this excerpt alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donahue Kevin Michael

(Last) (First) (Middle)

2502 KIRBY STREET

(Street)

DALLAS TX 75204

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAINZ BIOMED N.V. [ MYNZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
01/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/17/2025		P		685,000	A	$1.51	685,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Correction to Form 4 filed on 1/16/2026

	Kevin Donahue	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Mainz Biomed (MYNZ) report in this Form 4/A?

The filing reports that director Kevin Donahue purchased 685,000 shares of Mainz Biomed N.V. common stock on 10/17/2025, coded as a "P" (purchase) transaction.

At what price did Kevin Donahue buy Mainz Biomed (MYNZ) shares?

Kevin Donahue bought the 685,000 Mainz Biomed common shares at a price of $1.51 per share according to the Form 4/A.

How many Mainz Biomed (MYNZ) shares does Kevin Donahue own after this transaction?

After the reported transaction, Kevin Donahue is shown as beneficially owning 685,000 shares of Mainz Biomed common stock in a direct ownership account.

What is Kevin Donahue’s relationship to Mainz Biomed (MYNZ)?

The report identifies Kevin Donahue as a director of Mainz Biomed N.V.. The 10% owner box is not checked in the relationship section.

Why is this Mainz Biomed (MYNZ) insider filing labeled Form 4/A?

It is labeled as a Form 4/A because it is an amendment to a prior Form 4 originally filed on 01/16/2026, correcting previously reported information.

Does this Form 4/A indicate indirect ownership for Kevin Donahue in Mainz Biomed?

No. The filing lists the ownership form of the 685,000 shares as Direct (D), and no nature of indirect beneficial ownership is provided.